| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 922.73% | Cantor Fitzgerald | → $18 | Reiterates | Overweight → Overweight |
| 07/17/2023 | 922.73% | Cantor Fitzgerald | → $18 | Reiterates | Overweight → Overweight |
| 07/10/2023 | 922.73% | Cantor Fitzgerald | → $18 | Reiterates | Overweight → Overweight |
| 07/03/2023 | 922.73% | Cantor Fitzgerald | $18 → $18 | Reiterates | Overweight → Overweight |
| 06/05/2023 | 581.82% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 06/05/2023 | 468.18% | EF Hutton | → $10 | Reiterates | Buy → Buy |
| 05/26/2023 | 468.18% | EF Hutton | → $10 | Reiterates | Buy → Buy |
| 05/26/2023 | 581.82% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 05/25/2023 | 468.18% | EF Hutton | → $10 | Reiterates | Buy → Buy |
| 05/25/2023 | 581.82% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 05/17/2023 | 922.73% | Cantor Fitzgerald | → $18 | Reiterates | Overweight → Overweight |
| 05/11/2023 | 468.18% | EF Hutton | → $10 | Reiterates | Buy → Buy |
| 05/11/2023 | 581.82% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 03/16/2023 | 581.82% | HC Wainwright & Co. | $7 → $12 | Maintains | Buy |
| 02/21/2023 | 297.73% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/14/2023 | 468.18% | EF Hutton | → $10 | Maintains | Buy |
| 01/05/2023 | 468.18% | EF Hutton | → $10 | Initiates Coverage On | → Buy |
| 11/14/2022 | 13.64% | Piper Sandler | $6 → $2 | Maintains | Overweight |
| 10/25/2022 | 297.73% | HC Wainwright & Co. | $26 → $7 | Maintains | Buy |
| 06/03/2022 | 752.27% | Roth Capital | → $15 | Initiates Coverage On | → Buy |
| 03/08/2021 | 1377.27% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 09/18/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/23/2020 | 1377.27% | HC Wainwright & Co. | $15 → $26 | Maintains | Buy |
| 03/27/2020 | 752.27% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 12/20/2019 | 1320.45% | HC Wainwright & Co. | $31 → $25 | Maintains | Buy |
| 12/10/2019 | 1604.55% | Cantor Fitzgerald | → $30 | Initiates Coverage On | → Overweight |
| 11/20/2019 | 1661.36% | HC Wainwright & Co. | $18 → $31 | Reiterates | → Buy |
| 11/19/2019 | 1945.45% | Piper Sandler | $15 → $36 | Maintains | Overweight |
| 10/10/2019 | 922.73% | HC Wainwright & Co. | → $18 | Initiates Coverage On | → Buy |
| 05/13/2019 | 468.18% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 04/09/2019 | 695.45% | Wedbush | → $14 | Initiates Coverage On | → Outperform |
What is the target price for Aravive (ARAV)?
The latest price target for Aravive (NASDAQ: ARAV) was reported by Cantor Fitzgerald on July 21, 2023. The analyst firm set a price target for $18.00 expecting ARAV to rise to within 12 months (a possible 922.73% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aravive (ARAV)?
The latest analyst rating for Aravive (NASDAQ: ARAV) was provided by Cantor Fitzgerald, and Aravive reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Aravive (ARAV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aravive, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aravive was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
Is the Analyst Rating Aravive (ARAV) correct?
While ratings are subjective and will change, the latest Aravive (ARAV) rating was a reiterated with a price target of $0.00 to $18.00. The current price Aravive (ARAV) is trading at is $1.76, which is within the analyst's predicted range.